Neuroblastoma and Osteomedullary Disease
Clinical research is centered on high-risk neuroblastoma, with particular attention to patients who have primary refractory disease or an incomplete response after salvage treatment involving bone and bone marrow.
- Refractory neuroblastoma
- Bone marrow involvement
- Osteomedullary disease
The therapeutic focus includes antibody-based treatment strategies combined with immune-supportive approaches for difficult-to-treat pediatric solid tumors.
Oncology Immunotherapy
The sponsor’s research activity includes immunotherapy for pediatric oncology, with interest in treatments designed to support anti-tumor activity in advanced neuroblastoma.
- Antibody therapy
- Granulocyte-macrophage colony-stimulating factor
- Immune-mediated tumor response
Clinical work is directed toward improving disease control in patients with limited response to prior therapy.
Pediatric Solid Tumors
Research interest extends to childhood cancer, especially aggressive solid tumors requiring specialized treatment in relapsed or treatment-resistant settings.
- Pediatric cancer
- Relapsed disease
- Treatment-resistant malignancy
The funded trial activity reflects a focus on rare pediatric malignancies with significant unmet therapeutic need.
